Search clinical trials for: ACRA

Total 967 results

M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Myeloma

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Leukemia, Myelocytic, Acute
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Withdrawn

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes (CLO2009AISSM05)

Myelodysplastic Syndromes

Italy
Peking Union Medical College Hospital

Unknown

Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia

Autoimmune Anemia

China
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
New York Medical College

Unknown

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Myelogenous Leukemia | Burkitts Leukemia/Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
St. Petersburg State Pavlov Medical University

Terminated

Nivolumab With Chemotherapy in Refractory MDS

Myelodysplastic Syndromes

Russian Federation
Zhongnan Hospital
Shanxi Province Cancer Hospital; Ruijin Hospital; The First Affiliated Hospital... and other collaborators

Recruiting

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukaemia

China
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

AML Therapy With Irradiated Allogeneic Cells

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate (LAL1913)

Secondary | De Novo | Untreated Philadelphia Positive Acute Lymphoblastic Leukemia | Low-dose Corticosteroids Pretreatment

Italy
University of California, San Francisco
CellSight Technologies, Inc.

Withdrawn

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

Non-small Cell Lung Cancer
Kerry Rogers
Janssen Research & Development, LLC

Withdrawn

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Chronic Lymphocytic Leukemia | Loss of Chromosome 17p
Lactalis

Completed

Effect of a Mix of Dairy Lipids and Plant Oils in Infant Formula on Omega-3 Fatty Acid in Red Blood Cells (REBECA)

Infant Development

Italy
Nitya Jayaram-Lindstrom

Recruiting

Internet-based A-CRA for Young Adults With Problematic Alcohol Use (I-A-CRA)

Binge Drinking | Alcohol Use Disorder | Alcohol Abuse

Sweden
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
Universitätsklinikum Hamburg-Eppendorf
Neovii Biotech; Clinical Trial Center North (CTC North GmbH & Co. KG)

Terminated

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial (COAST)

Relapsing-Remitting Multiple Sclerosis

Germany
Bio-Path Holdings, Inc.

Completed

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Ph1 Positive CML

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Weill Medical College of Cornell University

Terminated

Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
Ohio State University

Recruiting

Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness

Risk Behavior | Opioid Use Disorder | Dual Diagnosis | Homelessness | Mental Disorder in Adolescence | Housing Problems

United States
The University of Hong Kong

Recruiting

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Acute Promyelocytic Leukemia

Hong Kong
Associazione Italiana Ematologia Oncologia Pediatrica

Recruiting

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

Belgium, Netherlands, Czechia, Denmark, France, Germany, Ireland, Israel, Italy, Portugal, Spain, Sweden
PETHEMA Foundation

Recruiting

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Acute Myeloblastic Leukemia

Spain
Ciceri Fabio

Completed

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (FLAT-Auto)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Transplant-Related Hematologic Malignancy

Italy
PETHEMA Foundation

Completed

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Acute Myeloblastic Leukaemia

Spain
Queen Mary University of London
Medical Research Council; Celgene

Active, not recruiting

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (STARPAC2)

Pancreatic Cancer

United Kingdom
Antisoma Research

Terminated

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Taiwan, Australia, New Zealand
Tecnoquimicas

Completed

Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate

Healthy

Brazil
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Unresectable Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Medical University of South Carolina

Terminated

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

Glioma | Astrocytoma | Brain Tumor | Glioblastoma Multiforme

United States
rEVO Biologics

Completed

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

Preeclampsia

United States
University of California, Davis
Pharmacyclics LLC.

Completed

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Metastatic Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States, Canada, Singapore
All India Institute of Medical Sciences, New Delhi

Unknown

Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation (Ara-c)

Acute Myeloid Leukemia

India
Warner Chilcott

Completed

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I) (ASCEND I)

Ulcerative Colitis

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States
Technische Universität Dresden
German Federal Ministry of Education and Research; Groupe Francophone des Myelodysplasies and other collaborators

Active, not recruiting

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

Acute Promyelocytic Leukemia

France, Germany, Italy, Netherlands, Spain
University of California, San Diego

Completed

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation (ACA)

Rosacea

United States
German Breast Group
Gilead Sciences; ETOP IBCSG Partners Foundation; UNICANCER; Austrian Breast & Colorectal... and other collaborators

Active, not recruiting

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

France, Spain, Germany, Switzerland, Austria, Ireland, Belgium
University of Florida

Active, not recruiting

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
H. Lee Moffitt Cancer Center and Research Institute

Completed

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

Small Cell Lung Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States

Search clinical trials for: ACRA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations